WallStSmart

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 81710% more annual revenue ($13.38B vs $16.36M). HSIC leads profitability with a 3.0% profit margin vs -4.3%. HSIC earns a higher WallStSmart Score of 52/100 (C-).

HKPD

Avoid

27

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 3/9Altman Z: 3.84

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HKPD.

HSICUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$153.40

Current Price

$77.45

$75.95 discount

UndervaluedFair: $153.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HKPD2 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.8410/10

Safe zone — low bankruptcy risk

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

HKPD4 concerns · Avg: 2.8/10
Market CapQuality
$9.28M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.794/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.153/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HKPD

The strongest argument for HKPD centers on Price/Book, Altman Z-Score.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : HKPD

The primary concerns for HKPD are Market Cap, Operating Margin, Piotroski F-Score.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

HKPD profiles as a turnaround stock while HSIC is a value play — different risk/reward profiles.

HSIC is growing revenue faster at 6.3% — sustainability is the question.

HKPD generates stronger free cash flow (-106,393), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HSIC scores higher overall (52/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?